Trial Profile
Phase2 study of Carboplatin / Paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with pleural efussion in stage 4.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Jun 2016 Results of biomarker analysis published in the Anticancer Research
- 14 Mar 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 20 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.